Luis Palomera

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

María‐Victoria Mateos, Pilar Giraldo, Javier de la Rubia et al. · New England Journal of Medicine · 2013 · 582 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations · Full text

Medicine, Hematology, Pharmacology +17

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

María‐Victoria Mateos, JoséM. Hernández, M.B. Gómez Hernández et al. · Blood · 2006 · 389 citations · Full text

Medicine, Hematology, Oncology +15

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

María‐Victoria Mateos, Pilar Giraldo, Javier de la Rubia et al. · The Lancet Oncology · 2016 · 191 citations

Medicine, Hematology, Oncology +14

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome

Jesús F. San Miguel, Júlia Almeida, Gema Mateo et al. · Blood · 2002 · 159 citations · Full text

Medicine, Hematology, Immunology +16